Publications (9)

2021

  1. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1373-1387

  2. Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis

    Brain Pathology, Vol. 31, Núm. 6

2019

  1. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 176, Núm. 10, pp. 1585-1600

  2. Structure–effect relationships of novel semi-synthetic cannabinoid derivatives

    Frontiers in Pharmacology, Vol. 10

  3. Cannabidiol administration prevents hypoxia-ischemia-induced hypomyelination in newborn rats

    Frontiers in Pharmacology, Vol. 10, Núm. SEP

2018

  1. Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB1 receptor ligand antagonists

    Bioorganic and Medicinal Chemistry, Vol. 26, Núm. 1, pp. 295-307

  2. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis

    Biochemical Pharmacology, Vol. 157, pp. 217-226

2017

  1. Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)

    Pharmacological Research

2016

  1. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile

    Pharmacological Research, Vol. 110, pp. 205-215